Nutromics

Founded in 2017 by co-CEOs Peter Vranes and Hitesh Mehta, Nutromics has a mission to revolutionise healthcare through Continuous Molecular Monitoring (CMM), with a vision for a world with zero preventable deaths through personalized and timely molecular insights. Nutromics is developing a world-first medical wearable device (patch) comprised of two technologies: a microneedle array that provides pain-free access to interstitial fluid, just under the skin, and DNA sensor technology applied to the microneedle tips, streaming molecular insights converted into electrical signal and sent to clinicians via Bluetooth. Nutromics will complete world-first in-human clinical studies of its first DNA sensors in 2022, as well as its integrated alpha prototype device. FDA approval of the Company&s;s first product, a continuous monitor for the IV antibiotic vancomycin is planned for 2025, with a pipeline of new DNA sensors and products also under development.